Every GLP-1 start is a baseline you are not currently taking.
A weight-management patient starting an incretin is a metabolic workup waiting to happen — thyroid, lipids, glucose, liver, hormones. Taking it before the first injection is good medicine and it is a second cash-pay line.
Buy ten or more of any SKU and we match it, free, until your next order.
Shown on the General Wellness panel. Every panel in the catalogue works the same way.
Weight loss changes measurable things. Measure them.
This is the vertical with the strongest evidence behind the re-test, because the intervention reliably moves markers you can show a patient.
Roughly 138 ng/dL, pooled across 44 studies and 1,774 men. The best-evidenced claim in the whole catalogue.
Baseline before the first dose, re-test at ninety days.
Your opening order, yours once bought.
Obesity lowers total testosterone through aromatisation and SHBG suppression, and weight loss reverses part of it — +4.8 nmol/L pooled across 44 studies and 1,774 men, with 2.5–5.2 nmol/L in the incretin subgroup specifically. That is a mechanism and a measured effect. It is not a claim that a GLP-1 treats hypogonadism, and we will not let it be sold as one.
Start with one. Stack the second.
We recommend a lead panel from your patient mix rather than from our margin. These are the two that fit this room.
Before an incretin, this panel establishes thyroid, hepatic, renal, lipid and hormonal status — and afterwards the same panel is what shows the patient the change is real beyond the scale. It is also the panel that catches the untreated thyroid disease that was the actual problem.
It is not a TRT diagnostic on its own. Men's health clinics should ask about the reconfigured TRT Baseline build, which adds PSA, LH, FSH, SHBG, calculated free testosterone and reflexed prolactin.
This population is polypharmacy-heavy and the incretins sit alongside antidepressants, statins and analgesia. CYP2D6, CYP2C19 and CYP2C9 metabolizer status is a one-time swab that informs everything else you prescribe alongside.
It does not predict whether a drug will work. It describes metabolism, which is one input into a prescribing decision you make.
Every panel ships on the same terms. Adding one adds a revenue line without adding capital, space or chair time. The full catalogue is here.
You buy it. You price it. You keep the difference.
Populate the table with your own volume — these are our assumptions, not your numbers.
| New starts / month | Panels (baseline + 90-day) | You keep each | Monthly | Annual |
|---|---|---|---|---|
| 10 new starts | 20 | $130 | $2,600 | $31,200 |
| 25 new starts | 50 | $130 | $6,500 | $78,000 |
| 50 new starts | 100 | $130 | $13,000 | $156,000 |
Two panels per new start in year one. Peptide margin on the incretin line itself is separate and bought at clinic pricing — tirzepatide 30 mg is $195 to you against a modelled $585 patient price.
Baseline. Treat. Prove it moved.
The panel is what makes everything else you sell repeatable, and it creates a second high-value visit per cycle.
Baseline
A panel establishes status before anything is prescribed.
Visit oneIntervention
Your protocol as today, plus whatever the panel indicated. That decision is yours, not ours.
Your protocolRe-test when indicated
A clinically indicated re-test shows what moved — and gives the patient a reason to come back and see it.
Visit twoShow the patient what it is
Two clips per panel, sized for a waiting-room screen or a social post. Download them from the poster page along with the print files.
What the General Wellness panel measures and how the sample is collected.
What the Pharmacogenetics (PGX) panel measures and how the sample is collected.
A poster for the waiting room.
Typeset, not AI-generated — so the text is correct and the claims match the standards page. A4 and US Letter for print, plus a square crop for social.
Your practice name can be added to the footer of any poster — send it with your application and we will supply a personalised set.
What you will ask first
Including the ones where the honest answer costs us the sale.
Do you supply the GLP-1s as well?
Yes, at clinic pricing on ordinary purchase terms — outside the panel match promotion, which covers diagnostic panels only. Supplied to licensed providers only, on a physician’s order.
Is the baseline clinically required?
No guideline mandates this specific panel, and we will not pretend one does. It is good practice and it is defensible; it is not a requirement, and a clinic that tells you otherwise is overselling.
What does the re-test actually show?
That markers moved. Weight is already on the scale — what the panel adds is the metabolic picture underneath it, which is what keeps a patient on a programme once the novelty of the number wears off.
Why PGX in a weight clinic?
Because this population is on more drugs than any other cash-pay vertical we sell into. It is not about the incretin; it is about everything prescribed alongside it.
What arrives
- Your opening order — buy ten or more and we match it
- One virtual training session for your team
- Provider portal access for results
- The CLIA certificate number and named assay methods
- Print-ready posters and the waiting-room video files
Panels are laboratory-developed tests performed by a CLIA-certified laboratory. They are not FDA-cleared for the indications described and do not diagnose, stage or grade disease. Economics shown are illustrative and not a guarantee of results.